Immunomet Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2015-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.immunomet.com
Clinical Trials
1
Active:0
Completed:1
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)Phase 1 Study of IM156 in Patients With Advanced Solid Tumor and Lymphoma
- First Posted Date
- 2017-09-05
- Last Posted Date
- 2020-10-19
- Lead Sponsor
- ImmunoMet Therapeutics, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT03272256
- Locations
- 🇰🇷
CHA Bundang Medical Center, Seongnam-si, Gyeonggi-do, Korea, Republic of
🇰🇷Asan Medical Center, Seoul, Korea, Republic of
🇰🇷Yonsei University Severance Hospital, Seoul, Korea, Republic of
News
No news found